|
1. Fauci AS, Harrison TR. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical. 2008; pp: 1006-20. 2. Alavi SM, Sanagooizadeh M, Rajabzadeh AR. [Determination of relationship between vit d3 deficiency and tuberculosis]. Iran J Infect Dis Trop Med. 2007; 11(35): 29-33. [Article in Persian] 3. Nasehi M, Mirhaghghani L. [National guideline for tuberculosis control]. 2nd ed. Tehran: Entesharate Andishmand. 2011; pp: 9-12. [Persian] 4. Amani F, Bashiri J, Sabzevari A, Gharoosi B, Nahanmoghaddam N. [Epidemiology of Tuberculosis in Ardabil, 2001-2005]. J Ardabil Univ Med Sci. 2007; 7(3): 236-41. [Article in Persian] 5. Hosseini S M J, Morovvati S, Ghadiani M H, Ranjbar R, Farnia M. [Epidemiologic study of TB in Iranian prisons during April-September 2004]. Sci J Forensic Med. 2007; 13(1): 7-10. [Article in Persian] 6. Asgharzadeh M, Alibakhshi A, Ranjbari J, Hanifi GhR, Khalili I, Razmaraei N, et al. [Study role of age in contact dependent transmission of Mycobacterium tuberculosis in northwest of Iran by IS6110-RFLP method]. Modares J Med Sci Pathol. 2009; 12(1): 11-16. [Article in Persian] 7. Tuberculosis: Treatment success Data by WHO region. Available at: http://apps.who.int/gho/data/ view.main.57196?lang=en.htm Accessed Aug 19, 2013 8. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb). 2003; 83(1-3): 183-6. 9. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study randomized controlled trial. JAMA. 2011 Apr; 305(14):1415-23. doi:10.1001/jama.2011.436 10. Bartacek A, Schütt D, Panosch B, Borek M; Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009 Jun; 13(6): 760-6. 11. Zhu L, Yan B, Ma W. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi. 1998 Nov; 21(11): 645-7. [Article in Chinese] 12. Cegolon L, Maguire H, Mastrangelo G, Carless J, Kruijshaar ME, Verlander NQ. Predictors of failure to complete tuberculosis treatment in London, 2003-2006. Int J Tuberc Lung Dis. 2010 Nov; 14(11): 1411-7. 13. Nasehi MM, Moosazadeh M, Amiresmaeili M R, Parsaee M R, Nezammahalleh A. [The epidemiology of factors associated with screening and treatment outcomes of patients with smear positive pulmonary tuberculosis: a population-based study]. J Mazandaran Univ Med Sci. 2012; 21(1): 9-18. [Article in Persian] 14. Saeidinia A, Taramian S, Keihanian F. [Evaluation of treatment results of the patients with tuberculosis]. J Guilan Uni Med Sci. 2014; 23(2): 7-13. [Article in Persian] 15. Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaoui I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health. 2011; 11: 140. doi:10.1186/1471-2458-11-140 16. Khazaei S, Kousehlou Z, Karami M, Zahiri A, Bathaei J. [Time to sputum conversion among patients with smear-positive pulmonary tuberculosis and its determinants: a retrospective cohort study in Hamadan province, Iran]. Iran J Epidemiol. 2013; 9(1): 32-40. [Article in Persian] 17. Keane VP, de Klerk N, Krieng T, Hammond G, Musk AW. Risk factors for the development of non-response to first-line treatment for tuberculosis in southern Vietnam. Int J Epidemiol. 1997 Oct; 26(5): 1115-20. 18. Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, El Rhazi K, et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011; 15(6): 838-43. 19. Panghea P, Anastasatu C. [Factors in the failure of tuberculosis chemotherapy studied in a Romanian county]. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1989 Jan-Mar; 38(1): 31-8. [Article in Romanian] 20. Adineh HA, Motametdi B, Veisi M, Bagheri S. [Risk factors of tuberculosis treatment failure in South-East of Iran]. J Gorgan Uni Med Sci. 2014; 16(2): 50-56. [Article in Persian] 21. Farazi AA, Jabbari Asl M, Sofian M. [Effects of sputum smear pullution intensity in pulmonary tuberculosis patients on treatment response]. Journal of Medical Council of Iran. 2011: 29(2): 150-6. [Article in Persian] 22. Miller M, Masztalerz J. [Characterization of patients with treatment failure in the Central Tuberculosis Registry]. Pneumonol Alergol Pol. 1995; 63(1-2): 21-6. [Article in Polish] 23. de Albuquerque Mde F, Ximenes RA, Lucena-Silva N, de Souza WV, Dantas AT, Dantas OM, et al. Factors associated with treatment failure, dropout, and death in a cohort of tuberculosis patients in Recife, Pernambuco State, Brazil. Cad Saude Publica. 2007 Jul; 23(7): 1573-82.
|
